DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY
The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and nec...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MULLINS, Stefanie PATKI, Abhay READER, Claire MORROW, Michelle |
| description | The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and neck in human patients.
La présente invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie au ligand de mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) en combinaison avec le paclitaxel, et leur utilisation médicale dans le traitement du carcinome à cellules squameuses de la tête et du cou chez des patients humains. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024194482A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024194482A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024194482A13</originalsourceid><addsrcrecordid>eNqNzLEKwjAQgOEuDqK-w4GzYGsHO17TS3NDciUJlE61SJxEC_X9UdAHcPqXj3-dXRoJ2BJ4atmSC6DFQzQE2Fh2HKLHyOJANCDUHDpSrFkBusi1NAOwAyW2Zvd1PUcDypCVz8RjN2yz1W26L2n36ybba4rKHNL8HNMyT9f0SK-xl-JYlHlVlucC89N_6g021DRK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY</title><source>esp@cenet</source><creator>MULLINS, Stefanie ; PATKI, Abhay ; READER, Claire ; MORROW, Michelle</creator><creatorcontrib>MULLINS, Stefanie ; PATKI, Abhay ; READER, Claire ; MORROW, Michelle</creatorcontrib><description>The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and neck in human patients.
La présente invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie au ligand de mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) en combinaison avec le paclitaxel, et leur utilisation médicale dans le traitement du carcinome à cellules squameuses de la tête et du cou chez des patients humains.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240926&DB=EPODOC&CC=WO&NR=2024194482A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25551,76302</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240926&DB=EPODOC&CC=WO&NR=2024194482A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MULLINS, Stefanie</creatorcontrib><creatorcontrib>PATKI, Abhay</creatorcontrib><creatorcontrib>READER, Claire</creatorcontrib><creatorcontrib>MORROW, Michelle</creatorcontrib><title>DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY</title><description>The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and neck in human patients.
La présente invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie au ligand de mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) en combinaison avec le paclitaxel, et leur utilisation médicale dans le traitement du carcinome à cellules squameuses de la tête et du cou chez des patients humains.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzLEKwjAQgOEuDqK-w4GzYGsHO17TS3NDciUJlE61SJxEC_X9UdAHcPqXj3-dXRoJ2BJ4atmSC6DFQzQE2Fh2HKLHyOJANCDUHDpSrFkBusi1NAOwAyW2Zvd1PUcDypCVz8RjN2yz1W26L2n36ybba4rKHNL8HNMyT9f0SK-xl-JYlHlVlucC89N_6g021DRK</recordid><startdate>20240926</startdate><enddate>20240926</enddate><creator>MULLINS, Stefanie</creator><creator>PATKI, Abhay</creator><creator>READER, Claire</creator><creator>MORROW, Michelle</creator><scope>EVB</scope></search><sort><creationdate>20240926</creationdate><title>DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY</title><author>MULLINS, Stefanie ; PATKI, Abhay ; READER, Claire ; MORROW, Michelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024194482A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MULLINS, Stefanie</creatorcontrib><creatorcontrib>PATKI, Abhay</creatorcontrib><creatorcontrib>READER, Claire</creatorcontrib><creatorcontrib>MORROW, Michelle</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MULLINS, Stefanie</au><au>PATKI, Abhay</au><au>READER, Claire</au><au>MORROW, Michelle</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY</title><date>2024-09-26</date><risdate>2024</risdate><abstract>The present invention relates to dosage regimens for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) in combination with paclitaxel, and their medical use in the treatment of squamous cell carcinoma of the head and neck in human patients.
La présente invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie au ligand de mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) en combinaison avec le paclitaxel, et leur utilisation médicale dans le traitement du carcinome à cellules squameuses de la tête et du cou chez des patients humains.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2024194482A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSAGE REGIMENS FOR THE ADMINISTRATION OF A BISPECIFIC ANTIBODY IN COMBINATION WITH CHEMOTHERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MULLINS,%20Stefanie&rft.date=2024-09-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024194482A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |